FOLH1 and prostate carcinoma: The OLI-P study published by Holscher et al. [10] was similar to ours (MDT without ADT for oligometastatic prostate cancer, guided by PSMA PET) and described a very similar failure free survival (22% at 3 years) and a local control rate of 93%.